Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2007

View Archived Issues

Novel oncolytic drugs revealed in recent patents

Merck & Co. reports third quarter 2007 results

Recent patents disclose new antiinfective agents

Antisense oligonucleotide reverses myotonia in mouse models of MD

Recent ACRAF patent discloses new antipyretic agents

HDAC5 function in nucleus accumbens altered by chronic cocaine and stress

Addex and Merck & Co. collaboration for Parkinson's disease

Novartis and MorphoSys form new strategic alliance

Acorda completes enrollment of phase III clinical trial of Fampridine-SR

Abbott makes Aluvia available to Ugandan children with HIV/AIDS

TopoTarget reports positive results from phase II clinical trial of Baceca

Buck Institute and Neurobiological Technologies to develop FGF-2 drug for HD

GW Pharmaceuticals initiates phase III clinical trial of Sativex for MS spasticity

InSite Vision files new drug submission with Health Canada for AzaSite for conjunctivitis

FDA accepts Repros' proposal to initiate phase III studies of Proellex for uterine fibroids

FDA accepts Cephalon's NDA for Treanda in chronic lymphocytic leukemia

AstraZeneca completes enrollment in phase III ZEST study of Zactima for NSCLC

AVI-4658 granted fast track status for Duchenne muscular dystrophy

Can-Fite submits IND application to the FDA to initiate phase I clinical trials with CF-102

Medtronic files premarket approval application with FDA for Talent

Ono reports first half ended September 30, 2007 R&D highlights

Novel treatments for urological disorders reported in recent Astellas and Mitsubishi Tanabe patents

Recent Japan Tobacco patent discloses novel therapeutic agents for HCV infection

Centocor and Janssen-Cilag seek approval for ustekinumab from FDA and EMEA

EMEA accepts for filing UCB's MAA for Neupro for restless legs syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...